ô¼ö¼º ±ÙÀ§ÃàÁõ : ±âȸ Æò°¡ ¹× ¿¹Ãø(2023-2033³â)
Spinal Muscular Atrophy: Opportunity Assessment and Forecast 2023-2033
»óǰÄÚµå : 1520946
¸®¼­Ä¡»ç : GlobalData
¹ßÇàÀÏ : 2024³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 64 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 9,995 £Ü 13,704,000
Zip (Single User License) help
ZIPÆÄÀÏ º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 19,990 £Ü 27,408,000
Zip (Site License) help
ZIPÆÄÀÏ º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ÇÑ ºÎ¼­¿¡¼­ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 29,985 £Ü 41,112,000
Zip (Global License) help
ZIPÆÄÀÏ º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷(ÇØ¿Ü)ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

7°³ ÁÖ¿ä ½ÃÀå Àüü¿¡¼­ ô¼ö¼º ±ÙÀ§ÃàÁõ(SMA) Áø´ÜÀ» ¹ÞÀº À¯º´ÀÚ ¼ö´Â 2023³â 18,621¸í¿¡¼­ 2033³â 19,202¸íÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÁÖ¿ä 7°³±¹ Àüü SMA ½ÃÀå ±Ô¸ð´Â 2023³â ±âÁØ 27¾ï ´Þ·¯·Î, 10³â°£ ¿¬Æò±Õ 1.2% ¼ºÀåÇÏ¿© 2033³â¿¡´Â 30¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

SMA ½ÃÀåÀÇ ¼ºÀå ÃËÁø¿äÀÎÀº ¿¹Ãø ±â°£ µ¿¾È Ãâ½Ã ¿¹Á¤ÀÎ 3°³ÀÇ ¹Ì¿À½ºÅ¸Æ¾ ¾ïÁ¦Á¦°¡ 2033³â±îÁö 2¾ï 5,940¸¸ ´Þ·¯ÀÇ ¸ÅÃâÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Á¹°Õ¸¶ÀÇ Á¤¸ÆÁÖ»ç Á¦Á¦ÀÇ ÀûÀÀÁõ È®´ë¿Í Á¹°Õ¸¶ÀÇ Ã´¼ö°­ ³» Á¦Á¦ ½ÂÀÎÀ¸·Î À¯ÀüÀÚ µµÀÔ ¿ä¹ýÀÇ ´ë»ó Àα¸°¡ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾È ½ºÇɶóÀÚÀÇ Æ¯Çã°¡ ¸¸·áµÉ °ÍÀ¸·Î ¿¹»óµÊ¿¡ µû¶ó Àú·ÅÇÑ ´©½Ã³Ú¼¾ ¹ÙÀÌ¿À½Ã¹Ð·¯°¡ ½ÃÀå¿¡ ÁøÀÔÇÏ¿© ¸ÅÃâÀÌ °¨¼ÒÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä 7°³±¹(¹Ì±¹, ÇÁ¶û½º, µ¶ÀÏ, µ¶ÀÏ, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ, ¿µ±¹, ÀϺ»)ÀÇ Ã´¼ö¼º ±ÙÀ§ÃàÁõ ½ÃÀåÀ» Á¶»çÇÏ¿© ½ÃÀå ¹× Áúȯ °³¿ä¿Í ÇÔ²² ȯÀÚ µ¿Çâ, ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®, 2033³â±îÁöÀÇ ¿¹Ãø µîÀ» Á¤¸®ÇÏ¿´½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Áúȯ °³¿ä

Á¦4Àå ¿ªÇÐ

Á¦5Àå ÇöÀç Ä¡·á ¿É¼Ç

Á¦6Àå ¹ÌÃæÁ· ¼ö¿ä¿Í ±âȸ

Á¦7Àå ¿¬±¸°³¹ß Àü·«

Á¦8Àå ÆÄÀÌÇÁ¶óÀÎ Æò°¡

Á¦9Àå ½ÃÀå Àü¸Á

Á¦10Àå ºÎ·Ï

Á¦11Àå ¹®ÀÇ

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The diagnosed prevalent cases of SMA across the seven major markets are expected to increase from 18,621 cases in 2023 to 19,202 cases by 2033.

The SMA market across the 7MM was valued at $2.7 billion in the 2023 baseline year. Over the 10-year forecast period, the market is projected to grow at a compound annual growth rate (CAGR) of 1.2%, reaching $3.0 billion by 2033.

A key driver of growth for the SMA market is the launch of three myostatin inhibitors anticipated to launch during the forecast period will contribute $259.4 million in sales by 2033. Label expansion of the intravenous formulation of Zolgensma and approval of an intrathecal formulation of Zolgensma will increase the eligible population for gene transfer therapy. Spinraza's expected patent expiry during the forecast period will see cheap nusinersen biosimilars enter the market and reduce sales.

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Spinal Muscular Atrophy (SMA) market through 2033.

Scope

Reasons to Buy

Table of Contents

Table of Contents

1. Preface

2. Executive Summary

3. Disease Overview

4. Epidemiology

5. Current Treatment Options

6. Unmet Needs and Opportunities

7. R&D Strategies

8. Pipeline Assessment

9. Market Outlook

10. Appendix

11. Contact Us

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â